DOCSLIB.ORG

National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 1 National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 1. Selected Lipid Management Recommendations and Guidelines 1.1. General Lipid Recommendations and Guidelines 1.1.1. 2015 National Lipid Association recommendations for patient-centered management of dyslipidemia: Part-1, full report 1.1.2. 2015 National Lipid Association recommendations for patient-centered management of dyslipidemia: Part-2 1.1.3. 2017 Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association 1.1.4. 2017 American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease 1.1.5. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk 1.1.6. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) 1.1.7. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the ACC/AHA Task Force on Practice Guidelines 1.1.8. 2004 NCEP ATP III and Update 1.2. Familial Hypercholesterolemia 1.2.1. 2017 Managing the Challenging Homozygous Familial Hypercholesterolemia Patient: Academic Insights and Practical Approaches for Severe Dyslipidemia: A National Lipid Association Masters Summit* 1.2.2. 2016 Defining severe familial hypercholesterolemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel 1.2.3. 2015 The Agenda for Familial Hypercholesterolemia: A Scientific Statement from the American Heart Association 1.2.4. 2014 Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation 1.2.5. 2014 Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society* 1.3. Children and Adolescents 1.3.1. 2016 Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement 1.3.2. 2016 Final Recommendation Statement from the U.S. Preventive Services Task Force Lipid Disorders in Children and Adolescents: Screening 1.3.3. 2015 EAS Consensus Statement on Familial Hypercholesterolemia in Children 1.4. Lipid-Altering Drug Safety 1.4.1. 2014 NLA Statin Safety Update 1.4.2. 2007 NLA Safety Task Force: The Non-statins 1.4.3. 2006 NLA Statin Safety Task Force 1.5. Other 1.5.1. 2017 Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association 1.5.2. 2016 Lipids and Bariatric Procedures Part 1 of 2: Scientific Statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association Revised January 2018 * Advanced National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 1.5.3. 2016 Lipids and Bariatric Procedures Part 2 of 2: Scientific Statement from the American Society for Metabolic and Bariatric Surgery, National Lipid Association, and Obesity Medicine Association 1.5.4. 2013 Chronic Kidney Disease Clinical Practice Guideline for Lipid Management 1.5.5. 2013 Obesity, Adiposity, and Dyslipidemia: A Consensus Statement from the National Lipid Association 1.5.6. 2011 NLA Expert Panel on Biomarkers: Clinical utility of inflammatory markers and advanced lipoprotein testing 1.5.7. 2011 AHA Scientific Statement on Triglycerides and CVD 1.5.8. 2010 EAS Consensus Statement on Lp(a) 2. Lipids and/or Lipid Treatment Targets 2.1. Non–High-Density Lipoprotein Cholesterol (non–HDL-C) 2.2. Low-Density Lipoprotein Cholesterol (LDL-C) 2.3. Apolipoprotein B (apo B) 2.4. LDL Particle Number 2.5. Triglycerides 2.6. High-Density Lipoprotein Cholesterol (HDL-C) 2.7. Lipoprotein (a) 2.8. Chylomicrons 2.9. Very-Low Density Lipoproteins (VLDL) 2.10. Intermediate Density Lipoproteins 2.11. Lipoprotein Remnants (Chylomicron, VLDL, etc.) 3. Non-lipid Biomarkers* 3.1. High Sensitivity CRP 3.2. Interleukin-1 3.3. Pro-BNP 3.4. Cardiac Troponin I and T 3.5. Lp-PLA2 4. Lipid Testing Methodologies 4.1. Fasting vs Non-Fasting Lipid Testing 4.2. Plasma or Serum Cholesterol and Triglyceride Levels [e.g., Automated Enzymatic Analyses Standardized via the Center for Disease Control’s (CDC) Lipid Standardization program] 4.3. HDL Cholesterol (e.g., Precipitation and Ultracentrifugation) 4.4. Low-Density Lipoprotein Cholesterol (LDL-C) Levels 4.4.1. Calculated (e.g., Friedewald Equation, Martin-Hopkins Equation) 4.4.2. Direct Measurements (e.g., Ultracentrifugation and Precipitation known as “beta- quantification” or “beta quant”) 4.5. Non-High-Density Lipoprotein Cholesterol (e.g., Calculated) 4.6. Apolipoprotein B (apo B) (e.g., Enzyme-linked Immunosorbent Assay)* 4.7. Lipoproteins* Revised January 2018 * Advanced National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 4.7.1. Gradient gel electrophoresis* 4.7.2. Tube gel electrophoresis* 4.7.3. Ultracentrifugation* 4.7.4. Vertical auto profile* 4.7.5. Nuclear magnetic resonance* 4.8. LDL particle number* 4.8.1. NMR* 4.8.2. Differential ion mobility analysis* 4.9. Lipoprotein(a) or Lp(a) (e.g., Standardized Immunoassays)* 4.10. Remnant Lipoprotein Particles* 4.10.1. Immunoseparation* 4.10.2. Vertical auto profile* 4.10.3. Calculation method (total cholesterol minus HDL-cholesterol minus LDL-Cholesterol)* 4.11. LDL Particle Size* 4.11.1. Segmented gradient gel electrophoresis* 4.11.2. Vertical auto profile ultracentrifugation* 4.11.3. Nuclear magnetic resonance* 5. Lipoproteins and Lipoprotein metabolism* 5.1. Lipoprotein Structure and Function 5.2. Intestinal Lipid Transport and Chylomicron Formation, Secretion and Catabolism* 5.3. Hepatic Lipid Transport and VLDL Formation, Secretion and Catabolism* 5.4. LDL Receptor Expression, Function and Catabolism (PCSK9)* 5.5. HDL Synthesis, Maturation, Catabolism, Role in Peripheral / Reverse Cholesterol Transport and Non-ASCVD Effects* 5.6. Cholesterol and Bile Acid Metabolism* 5.7. Microbiome 5.8. Intrahepatic Gene Regulation via Nuclear Receptor Factors* 5.8.1. LXR 5.8.2. FXR 5.8.3. PPAR 5.8.4. SREBP 6. Vascular Biology* 6.1. Normal Arterial Biology* 6.2. Pathogenesis of Atherosclerosis* 6.3. Thrombosis* 6.4. Inflammation* 7. Atherosclerotic Cardiovascular Disease Risk Assessment 7.1. ASCVD Risk Factors (2014 NLA Recommendations Part 1) 7.1.1. Prior or Current Coronary Artery Disease or ASCVD 7.1.1.1. Myocardial Infarction 7.1.1.2. Coronary Stenosis 7.1.1.3. Stroke 7.1.1.4. Carotid Stenosis Revised January 2018 * Advanced National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 7.1.1.5. Other Large Artery Atherosclerosis 7.1.1.6. Peripheral Vascular Disease 7.1.1.7. Aortic Aneurysm 7.1.2. Family History of Premature ASCVD 7.1.3. High Blood Pressure 7.1.4. Cigarette Smoking 7.1.5. Diabetes Mellitus 7.1.6. Obesity 7.1.7. Metabolic Syndrome 7.1.8. History of Preeclampsia, Gestational Diabetes, or Pregnancy-induced Hypertension 7.1.9. Renal Disease (e.g., Microalbuminuria, Chronic Kidney Disease) 7.1.10. Inflammatory Diseases 7.1.10.1. Human Immune Virus 7.1.10.2. Rheumatoid Arthritis 7.1.10.3. Systemic Lupus Erythematosus 7.1.11. Solid Organ Transplant 7.2. Subclinical Atherosclerosis Evaluation 7.2.1. Coronary Artery Calcium Scoring 7.2.2. Coronary Computed Tomography Angiography (CCTA) 7.2.3. Carotid Intima-media Thickness and Plaque 7.2.4. Ankle-brachial Index 7.3. ASCVD Risk and Other Calculators 7.3.1. American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Estimator 7.3.2. Lifetime ASCVD Risk Calculators 7.3.2.1. ACC/AHA Lifetime Risk Calculator 7.3.2.2. Framingham Lifetime Risk Calculator 7.3.3. Predominantly US Risk Assessment Calculators / Estimators 7.3.3.1. United States National Heart, Lung, and Blood Institute Framingham Risk Score 7.3.3.2. Multi-Ethnic Study of Atherosclerosis (MESA) 10-Year CHD Risk with Coronary Artery Calcification Risk Score 7.3.3.3. Reynolds Risk Score 7.3.3.4. Strong Heart Study Risk Calculator* 7.3.4. Predominantly International Risk Assessment Calculators / Estimators 7.3.4.1. QRISK Risk Calculator* 7.3.4.2. Systemic Coronary Risk Estimation (SCORE)* 7.3.4.3. Prospective Cardiovascular Munster Study (PROCAM)* 7.3.4.4. National Health Service (NHS) Health Check* 7.3.5. American College of Cardiology Statin Intolerance App 8. Atherosclerotic Cardiovascular Disease (ASCVD) Risk Categories 8.1. Very-High Cardiovascular Disease Risk 8.2. High Cardiovascular Disease Risk 8.3. Moderate Cardiovascular Disease Risk 8.4. Low Cardiovascular Disease Risk Revised January 2018 * Advanced National Lipid Association (NLA) Core Curriculum in Clinical Lipidology 9. Lipid Treatment Targets, Goals, Thresholds, and Screening 9.1. Definitions 9.1.1. Lipid Targets 9.1.2. Lipid Goals 9.1.3. Lipid Thresholds 9.2. Lipid Screening 9.3. Lipid Treatment Goals and Thresholds 9.3.1. Non-HDL-C 9.3.2. LDL-C 9.3.3. Triglycerides 9.3.4. Apolipoprotein B 10. Genetic Dyslipidemias 10.1. Physical Findings 10.1.1. Xanthomas 10.1.2. Xanthelasma (including Non-Hyperlipidemic Causes) 10.1.3. Corneal Arcus 10.1.4. Lipemia Retinalis 10.1.5. Apple Versus Pear Body Fat Distribution 10.1.6. “Test Tube” Blood Appearance 10.2. Hypolipidemias 10.2.1. Hypoalphalipoproteinemia Syndromes (deficiencies in APOA1, apoA1milano, ABCA1 (Tangiers), ABCG1, LCAT (Fish Eye Disease) 10.2.2. Abetalipoproteinemia (MTP deficiency) 10.2.3. Hypobetalipoproteinemias 10.2.4. PCSK9 Loss of Function 10.2.5. ANGTL 3 Loss of Function 10.3. Major Lipid Associated Genes (GWAS Studies)* 10.3.1. LDL - LDLR, APOB, PCSK9, APOB, HMGCR, NPC1L1, LDLRAP1, SORT1, ABCG5/ABCG8, CYP27A1 10.3.2.
Load more

Recommended publications
  • National Lipid Association Annual Summary of Clinical Lipidology 2015
    Journal of Clinical Lipidology (2014) 8, S1-S36 Original Contribution National Lipid Association Annual Summary of Clinical Lipidology 2015 Harold E. Bays, MD, FTOS, FACC, FACE, FNLA*, Peter H. Jones, MD, FACP, FNLA, W. Virgil Brown, MD, FNLA, Terry A. Jacobson, MD, FACP, FNLA Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr Bays); Baylor College of Medicine, Houston, TX, USA (Dr Jones); Emory University School of Medicine, Atlanta, GA, USA (Dr Brown); and Department of Medicine, Emory University, Atlanta, GA, USA (Dr Jacobson) KEYWORDS: Abstract: The National Lipid Association (NLA) Annual Summary of Clinical Lipidology 2015 is a Clinical Lipidology; summary of principles important to the patient-centered evaluation, management, and care of patients Dyslipidemia; with dyslipidemia. This summary is intended to be a ‘‘living document,’’ with future annual updates National Lipid based on emerging science, clinical considerations, and new NLA Position and Consensus Statements. Association; The goal is to provide clinicians an ongoing resource that translates the latest advances in medical Annual Summary; science toward the evaluation and treatment of patients with dyslipidemia. The 2015 NLA Annual Cholesterol; Summary of Clinical Lipidology was founded on the principles of evidence-based medicine and is Recommendations; generally consistent with established national and international lipid guidelines. Topics include a Guidelines general discussion of the 2014 NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, secondary causes of dyslipidemia, biomarkers and ‘‘advanced lipid testing,’’ medical nutrition, physical activity, obesity, pharmacotherapy, statin safety, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia in children and adolescence, dyslipidemia in older individuals, race/ethnicity, and women, health information technology and electronic medical records, as well as investigational lipid-altering drugs in development.
    [Show full text]
  • Geeta Sikand, MS
    Geeta Sikand, MA, RDN, FAND, CDE, CLS, FNLA Geeta Sikand is an Associate Clinical Professor of Medicine in Cardiology at the University of California, Irvine School of Medicine. Registered Dietitian Nutritionist, Clinical Lipid Specialist, Certified Diabetes Educator, Fellow of the National Lipid Association and Fellow of the Academy of Nutrition and Dietetics. Ms Sikand is Director of Nutrition at University of California Irvine Preventive Cardiology Program. Ms Sikand is the recipient of the 2016 Lifetime Achievement Award from the Academy of Nutrition and Dietetics Member Interest Group, the 2013 Distinguished Service Award from the Dietitians’ in Health Care Communities Practice Group. For her research on the effectiveness of medical nutrition therapy in dyslipidemia, Geeta was the 2001 recipient of the Academy of Nutrition & Dietetics prestigious "Mary Huddleson Award” and the 1997 Excellence in Research Award from the California Academy of Nutrition and Dietetics. Ms Sikand is Chair, Medical Nutrition Therapy Effectiveness Expert Workgroup of the Academy of Nutrition & Dietetics and served as Expert Member of the Disorders of Lipid Metabolism Expert Panel. Ms Sikand has served on the Board of Directors of the American Heart Association and as Vice President of Public Policy for California Dietetic Association. As President of California Dietetic Association: Orange District and Chair of Southern California Legislative Steering Committee Ms Sikand organized the first ever onsite Congressional visit with Congressman Ron Packard to seek his support for the Medicare medical nutrition therapy legislation which passed in 1996. Ms Sikand is a member of the Pacific Lipid Association (PLA) and has served on the National Lipid Association (NLA) Expert Panel “Recommendations for Patient Centered Management of Dyslipidemia” published in December 2015.
    [Show full text]
  • National Lipid Association Annual Summary of Clinical Lipidology 2016
    Journal of Clinical Lipidology (2016) 10, S1-S43 National Lipid Association Annual Summary of Clinical Lipidology 2016 Harold E. Bays, MD, FNLA*, Peter H. Jones, MD, FNLA, Carl E. Orringer, MD, FNLA, W. Virgil Brown, MD, FNLA, Terry A. Jacobson, MD, FNLA Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr Bays); Baylor College of Medicine, Houston, TX, USA (Dr Jones); University of Miami Leonard M. Miller School of Medicine, Miami, FL (Dr Orringer); Emory University School of Medicine, Atlanta, GA, USA (Dr Brown); and Department of Medicine, Emory University, Atlanta, GA, USA (Dr Jacobson) KEYWORDS: Abstract: The National Lipid Association (NLA) Annual Summary of Clinical Lipidology is a yearly Clinical Lipidology; updated summary of principles important to the patient-centered evaluation, management, and care Dyslipidemia; of patients with dyslipidemia. This summary is intended to be a ‘‘living document,’’ with future annual National Lipid updates based on emerging science, clinical considerations, and new NLA Position, Consensus, and Association; Scientific Statements, thus providing an ongoing resource that applies the latest in medical science to- Annual Summary; wards the clinical management of patients with dyslipidemia. Topics include the NLA Recommenda- Cholesterol; tions for Patient-Centered Management of Dyslipidemia, genetics, Familial Hypercholesterolemia, Recommendations; secondary causes of dyslipidemia, biomarkers and advanced lipid testing, nutrition, physical activity, Guidelines obesity, adiposopathy, metabolic syndrome, diabetes mellitus, lipid pharmacotherapy, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia management and treatment based upon age (chil- dren, adolescents, and older individuals), dyslipidemia considerations based upon race, ethnicity and gender, dyslipidemia and human immune virus infection, dyslipidemia and immune disorders, adher- ence strategies and collaborative care, and lipid-altering drugs in development.
    [Show full text]
  • Preventive Cardiology / Advanced Lipidology Clinical Fellowship
    Preventive Cardiology / Advanced Lipidology Clinical Fellowship Name of Institution: McGill University Health Centre Location: Cardiology Division, MUHC RVH Site, 687 Pine Avenue West Montreal, QC, H3A 1A1 MUHC RI, Cardiology Research Laboratories Type of Fellowship: Preventive Cardiology / Advanced Lipidology fellowship training program Duration: 1 year (Clinical and clinical research) Program Information This fellowship is offered to residents having completed Internal Medicine Residency, Medical Biochemistry Residency or Cardiology Residency. Exceptionally, physicians having completed family practice will be considered. Number of fellowship positions requested: One fellow per supervisor. Every fellowship will be reviewed to ensure that there are the appropriate resources for the fellow in terms of an educational experience. Training sites: McGill University Health Center Hospital involved in training: Royal Victoria Hospital where candidate will spend most of the time. Requirement: licensed MD who has completed a formal training program as outlined above. Scholarly activity will mainly be in research in the field of lipidology, and fellows will be expected to design and execute at least one research project in the area of atherosclerosis pathogenesis or lipid management during their training period. They will also be expected to work on publications. Areas of research experience to be emphasized include research design, recruitment techniques, data acquisition, and analysis. The fellow will be encouraged to present the research at national meetings and publish the data in established, peer-reviewed journals. The mission is to promote and advocate the understanding of dyslipidemia and primary prevention. The primary goal of this specialized training is to reduce the morbidity and mortality from dyslipidemia and related diseases by bridging basic knowledge and recent understanding of the vascular biology and their relevance to the basis of high risk screening and prevention of disease in a clinical setting.
    [Show full text]
  • JOURNAL of CLINICAL LIPIDOLOGY Official Journal of the National Lipid Association
    JOURNAL OF CLINICAL LIPIDOLOGY Official Journal of the National Lipid Association AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.1 • Impact Factor p.2 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.5 ISSN: 1933-2874 DESCRIPTION . The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
    [Show full text]
  • SIRT1 Regulates Sphingolipid Metabolism and Neural
    RESEARCH ARTICLE SIRT1 regulates sphingolipid metabolism and neural differentiation of mouse embryonic stem cells through c-Myc- SMPDL3B Wei Fan1, Shuang Tang1†, Xiaojuan Fan2, Yi Fang1, Xiaojiang Xu3, Leping Li4, Jian Xu5, Jian-Liang Li3, Zefeng Wang2*, Xiaoling Li1* 1Signal Transduction Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Triangle Park, United States; 2CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China; 3Integrative Bioinformatics Support Group, National Institute of Environmental Health Sciences, Research Triangle Park, Triangle Park, United States; 4Biostatistics & Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, Triangle Park, United States; 5Children’s Medical Center Research Institute, Department of Pediatrics, Harold C. Simmons Comprehensive Cancer *For correspondence: Center, and Hamon Center for Regenerative Science and Medicine, University of [email protected] (ZW); Texas Southwestern Medical Center, Dallas, United States [email protected] (XL) Present address: †Cancer Institute and Department of Nuclear Medicine, Fudan Abstract Sphingolipids are important structural components of cell membranes and prominent University Shanghai Cancer signaling
    [Show full text]
  • Genetics and Mainstream Medicine
    Genetics and mainstream medicine Service development and integration March 2011 Author: Hilary Burton Acknowledgements The author would like to acknowledge with thanks the expert guidance and support of Dr Ron Zimmern and Dr Peter Farndon. The initial work was funded by the UK Genetic Testing Network. However, this final report is published independently by the PHG Foundation. This report can be downloaded from our website: www.phgfoundation.org Published by PHG Foundation 2 Worts Causeway Cambridge CB1 8RN UK Tel: +44 (0) 1223 740200 Fax: +44 (0) 1223 740892 © 2011 PHG Foundation ISBN 978-1-907198-07-6 Correspondence to the author: [email protected] How to reference this report: Genetics and mainstream medicine. PHG Foundation (2011) ISBN 978-1-907198-07-6 The PHG Foundation is the working name of the Foundation for Genomics and Population Health, an independent charitable organisation (registered in England and Wales, charity No. 1118664 company No. 5823194), which works with partners to achieve better health through the responsible and evidence-based application of biomedical science. Genetics and mainstream medicine – service development and integration Table of Contents Key policy points ...............................................................................3 1 Introduction ..............................................................................7 2 Background ...............................................................................9 3 Methods ................................................................................
    [Show full text]
  • 2015 National Lipid Association
    Journal of Clinical Lipidology (2015) -, -–- Original Contribution National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD*, Matthew K. Ito, PharmD, Kevin C. Maki, PhD, Carl E. Orringer, MD, Harold E. Bays, MD, Peter H. Jones, MD, James M. McKenney, PharmD, Scott M. Grundy, MD, PhD, Edward A. Gill, MD, Robert A. Wild, MD, PhD, Don P. Wilson, MD, W. Virgil Brown, MD Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA (Dr Jacobson); Oregon State University/Oregon Health & Science University, College of Pharmacy, Portland, OR, USA (Dr Ito); Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL, USA (Dr Maki); University of Miami Health System, Miami, FL, USA (Dr Orringer); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA (Dr Bays); Baylor College of Medicine, Houston, TX, USA (Dr Jones); Virginia Commonwealth University and National Clinical Research, Richmond, VA, USA (Dr McKenney); The University of Texas Southwestern Medical Center, Dallas, TX, USA (Dr Grundy); University of Washington/Harborview Medical Center, Seattle, WA, USA (Dr Gill); Oklahoma University Health Sciences Center, Oklahoma City, OK, USA (Dr Wild); Cook Children’s Medical Center, Fort Worth, TX, USA (Dr Wilson); and Emory University School of Medicine, Atlanta, GA, USA (Dr Brown) KEYWORDS: Abstract: The leadership of the National Lipid Association convened an Expert Panel to develop a Clinical consensus set of recommendations for patient-centered management of dyslipidemia in clinical med- recommendations; icine. An Executive Summary of those recommendations was previously published. This document Dyslipidemia; provides support for the recommendations outlined in the Executive Summary.
    [Show full text]
  • Therapeutic Lipidology
    springer.com Medicine : Cardiology Davidson, M.H., Toth, P.P., Maki, K.C. (Eds.) Therapeutic Lipidology Provides comprehensive coverage of all core aspects of clinical lipidology as well as relevant basic science and dyslipidemia management strategies Updated to include new guidelines, novel therapeutic agents, and changes in the understanding of specific lipids/lipoproteins and cardiovascular disease risk Highlights recent advances in the field such as novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, as well as imaging technologies and lipoprotein separation/measurement methodologies The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease. The book describes Humana new guidelines, novel therapeutic agents, and changes in the understanding of specific 2nd ed. 2021, XV, 689 p. lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. 2nd 140 illus., 114 illus. in color. edition The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle /dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an Printed book examination of other biomarkers and testing procedures related to atherosclerosis and Hardcover cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource Printed book for physicians, medical students, residents, fellows, and allied health professionals in lipidology, Hardcover cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.
    [Show full text]
  • Lipids and Bariatric Procedures Part 1 of 2: Scientific Statement from The
    Journal of Clinical Lipidology (2016) 10, 15–32 Scientific Statement from the National Lipid Association Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY Harold E. Bays, MD, FTOS, FACC, FACE, FNLA*, Peter H. Jones, MD, FNLA, Terry A. Jacobson, MD, FACP, FNLA, David E. Cohen, MD, PhD, Carl E. Orringer, MD, FACC, FNLA, Shanu Kothari, MD, FACS, Dan E. Azagury, MD, John Morton, MD, MPH, FACS, FASMBS, Ninh T. Nguyen, MD, FACS, FASMBS, Eric C. Westman, MD, MHS Diplomate ABOM, Deborah B. Horn, DO, MPH Diplomate ABOM, Wendy Scinta, MD, MS, Craig Primack, MD, FACP, FAAP Diplomate ABOM Louisville Metabolic and Atherosclerosis Research Center (L–MARC), Louisville, KY, USA (Dr Bays); Methodist DeBakey Heart and Vascular Center, Baylor College of Medicine, Houston, TX, USA (Dr Jones); Department of Medicine, Emory University, Atlanta, GA, USA (Dr Jacobson); Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA (Dr Cohen); University of Miami Hospital, Miami, FL, USA (Dr Orringer); Surgery Fellowship Program, Gundersen Medical Foundation, La Crosse, WI, USA (Dr Kothari); Stanford University School of Medicine, Stanford, CA, USA (Dr Azagury); Stanford University School of Medicine, Stanford, CA, USA (Dr Morton); University of California Medical Center, Orange, CA, USA (Dr Nguyen); Duke University Health System, Durham, NC, USA (Dr Westman); University of Texas Medical School, Houston, TX, USA (Dr Horn); Fayetteville, NY, USA (Dr Scinta); and Scottsdale Weight Loss, Scottsdale, AZ, USA (Dr Primack) KEYWORDS: Abstract: Bariatric procedures often improve lipid levels in patients with obesity.
    [Show full text]
  • Dietary Approaches for Managing Hyperlipidemia Erin Scarlett, MPH, RD December 7, 2018 Objectives by the End of This Session, Participants Will Be Able To
    Dietary Approaches for Managing Hyperlipidemia Erin Scarlett, MPH, RD December 7, 2018 Objectives By the end of this session, participants will be able to: • Identify sources of heart-healthy fats versus saturated fats • Describe how soluble fiber may be beneficial for lowering cholesterol Hyperlipidemia https://watchlearnlive.heart.org/CVML_Player.php?moduleSelect=chlscr US Dept of Health and Human Services, National Institutes of Health. (2005). High blood cholesterol: What you need to know. Bethesda, MD: National Heart, Lung, and Blood Institute. Medical Nutrition Therapy for Hyperlipidemia • Dietary recommendations currently from: • 2013 AHA/ACC Guideline of Lifestyle Management to Reduce Cardiovascular Risk (Eckel et al. 2013) • National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia -- Parts 1 & 2 (Jacobson et al. 2015a and b) • Dietary recommendations include: • Choose unsaturated fats over saturated and trans fats • Use non-tropical oils (canola, olive, avocado) • Eat plenty of fruits, vegetables, and whole grains • Include low-fat dairy, poultry, fish, legumes, unsalted nuts • Limit red meat, sodium, sugar-sweetened beverages (SSB), and sweets Saturated Fats (SFAs) •Increase LDL-cholesterol •NLA: SFA <7% of total energy intake • AHA/ACC: 5 – 6% intake •2000 calorie/day diet: • 5 – 7% intake of saturated fats = 11 – 15 g/day Replacing SFAs Li, Y., et al. 2015 Replacing SFAs • Replacing SFA with PUFA reduces the occurrence of CHD events by 19% • Each 5% greater intake of PUFA: • reduced CHD risk
    [Show full text]
  • Research Annual 2021 from the Chair
    chemical engineering & materials science Research Annual 2021 from the Chair reetings from the Department of Chemical nn Daniel Woldring, a postdoctoral fellow at Brandeis Engineering and Materials Science (ChEMS) at University, who joined us in the fall of 2019. He is an GMichigan State University! Since I last communicated assistant professor and will be working in the Institute to you in 2019, our University, our nation, and indeed the for Quantitative Health Science and Engineering. entire global community has been confronted with the Dr. Woldring’s research interests center on high trial of the COVID-19 pandemic. It certainly has been one performance therapeutics and diagnostics using novel of the most challenging periods in the history of our great protein engineering methods. institution. I am extremely proud of the concerted efforts of our students, staff, and faculty to meet these challenges nn faculty awards & honors head-on and continue our traditions of teaching, learning, Our faculty members continue to live up to their reputation and pushing back the boundaries of our understanding of as world class in service, teaching, and research, as is the world around us. reflected in the numerous prestigious awards and honors they have received this past year. Some highlights include: nn new faculty nn Robert Ofoli has accepted the position of Interim Faculty We have been very fortunate over the last two years to Excellence Advocate in the College of Engineering; have been able to continue our recruitment of new faculty. Several additions over this period have both broadened the nn Stephen Kamin was the recipient of the 2020 Withrow range of our research enterprise and provided greater depth Teaching Excellence Award; in key areas.
    [Show full text]